fda warning letters compounding semaglutide october 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded GLP-1 Drugs and Telehealth Providers Beyond the Headlines: FDA Warning

It has been used to help with fat metabolism in other species, and recent scientific studies show that it can help reduce weight in overweight dogs

Its a common insurance tactic to control costs and can cause significant delays in getting effective treatment

This news is one step in the direction of increasing access to these effective treatments for obesity

For more information: Caroline M

A later ADA conference presentation compared those outcomes to patients who subsequently received GLP-1 agonists and found similar long-term trajectories, though the comparison involved only five patients and wasn't a head-to-head trial [17]